JNJ250110P140000
- 0.10
- +0.07+233.33%
Johnson & Johnson Newsroom
Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $166
Johnson & Johnson Gets FDA Priority Review of Nipocalimab in Generalized Myasthenia Gravis
Express News | J&J: Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized Myasthenia Gravis (Gmg)
Express News | Arkuda Therapeutics: J&J Exercised Option to Buy Co's Portfolio of Lysosomal Function Enhancers for Upfront Payment & Extra Milestone Payments
Arkuda Therapeutics Announces Option Exercise and Asset Purchase
Johnson & Johnson's drug for treating Alzheimer's disease has received FDA fast track designation.
On January 9, Glonghui reported that Johnson & Johnson announced on Wednesday that its proposed drug posdinemab for the treatment of Alzheimer's disease has been granted Fast Track designation by the USA Food and Drug Administration (FDA). Johnson & Johnson is conducting a Phase 2b study on early Alzheimer's patients to investigate an internally developed tau-targeted monoclonal antibody. The company stated that posdinemab shows potential against disease-related phosphorylated tau proteins in the cerebrospinal fluid of Alzheimer's patients, and it has been shown to prevent the development and Diffusion of tau protein aggregation in nonclinical models of memory deprivation disease.
Bernstein Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Cuts Target Price to $160
San Francisco Police Cancel Time Off as Healthcare Execs Descend -- Barrons.com
Johnson & Johnson Temporarily Pulls New Treatment for Atrial Fibrillation to Probe Adverse Events
Johnson & Johnson Falls After Pausing Varipulse Cases
8 Health Care Stocks Whale Activity In Today's Session
Express News | J&J - as U.S. External Evaluation Leveraged Unique Platform Configuration, There Is No Impact to Commercial Activity & Varipulse Cases Outside of U.s
Express News | J&J: On Jan 5, Johnson & Johnson Medtech Temporarily Paused U.S. External Evaluation and All U.S. Varipulse Cases
Express News | Johnson & Johnson Statement on Varipulse™ U.S. External Evaluation
Merck, Johnson & Johnson Share Losses Lead Dow's 180-Point Fall
Johnson & Johnson on Track for Lowest Close Since November 2020 -- Data Talk
Johnson & Johnson (JNJ.US) Posdinemab treatment for Alzheimer's disease has received FDA fast track designation.
Pharmaceutical giant Johnson & Johnson (JNJ.US) announced on Wednesday that its proposed drug posdinemab for the treatment of Alzheimer's disease has received Fast Track designation from the USA Food and Drug Administration (FDA). Johnson & Johnson is conducting a Phase 2b study on early Alzheimer’s patients, focusing on an internally discovered tau-targeted monoclonal antibody. The company states that posdinemab has shown potential against the disease-causing phosphorylated tau protein in cerebrospinal fluid of Alzheimer’s patients and has been found to inhibit the development and diffusion of tau protein aggregation in non-clinical models of cognitive impairment.
Johnson & Johnson Gets FDA Fast-Track Designation for Posdinemab in Alzheimer's